Literature DB >> 19222668

Hyperkalemia as a constraint to therapy with combination Renin-Angiotensin system blockade: the elephant in the room.

Murray Epstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19222668      PMCID： PMC8673296          DOI： 10.1111/j.1751-7176.2008.00071.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  24 in total

Review 1.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.

Authors:  Biff F Palmer
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

2.  Hemodynamic and electrocardiographic effects of hyperpotassemia. Differences in response to slow and rapid increases in concentration of plasma K.

Authors:  B Surawicz; H Chlebus; A Mazzoleni
Journal:  Am Heart J       Date:  1967-05       Impact factor: 4.749

Review 3.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

4.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Authors:  T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

5.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 6.  Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.

Authors:  Murray Epstein
Journal:  Am J Med       Date:  2006-11       Impact factor: 4.965

7.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

8.  Red blood cell potassium and blood pressure in adolescents: a mixture analysis.

Authors:  M C Delgado; A Delgado-Almeida
Journal:  Nutr Metab Cardiovasc Dis       Date:  2002-06       Impact factor: 4.222

9.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

Authors:  G Maschio; D Alberti; G Janin; F Locatelli; J F Mann; M Motolese; C Ponticelli; E Ritz; P Zucchelli
Journal:  N Engl J Med       Date:  1996-04-11       Impact factor: 91.245

10.  Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Authors:  Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-19       Impact factor: 8.237
View more
  6 in total

1.  Multiple comorbid conditions and healthcare resource utilization among adult patients with hyperkalemia: A retrospective observational cohort study using association rule mining.

Authors:  Dingwei Dai; Ajay Sharma; Paula J Alvarez; Steven D Woods
Journal:  J Multimorb Comorb       Date:  2022-05-12

2.  Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.

Authors:  Pablo E Pergola; David M Spiegel; Suzette Warren; Jinwei Yuan; Matthew R Weir
Journal:  Am J Nephrol       Date:  2017-10-11       Impact factor: 3.754

Review 3.  Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.

Authors:  Gemma Currie; Alison H M Taylor; Toshiro Fujita; Hiroshi Ohtsu; Morten Lindhardt; Peter Rossing; Lene Boesby; Nicola C Edwards; Charles J Ferro; Jonathan N Townend; Anton H van den Meiracker; Mohammad G Saklayen; Sonia Oveisi; Alan G Jardine; Christian Delles; David J Preiss; Patrick B Mark
Journal:  BMC Nephrol       Date:  2016-09-08       Impact factor: 2.388

Review 4.  The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials.

Authors:  Murray Epstein; Meyer D Lifschitz
Journal:  Kidney Int Rep       Date:  2016-04-08

5.  The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.

Authors:  Marc Evans; Eirini Palaka; Hans Furuland; Hayley Bennett; Cecilia Linde; Lei Qin; Phil McEwan; Ameet Bakhai
Journal:  BMC Nephrol       Date:  2019-01-31       Impact factor: 2.388

6.  Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.

Authors:  Cecilia Linde; Ameet Bakhai; Hans Furuland; Marc Evans; Phil McEwan; Daniel Ayoubkhani; Lei Qin
Journal:  J Am Heart Assoc       Date:  2019-11-12       Impact factor: 5.501
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.